Correction to: Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM

Milind Y. Desai

Cleveland Clinic, Cleveland

Kathy Wolski

Cleveland Clinic Coordinating Center for Clinical Research, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland

Anjali Owens

Jeffrey B. Geske

Departments of Cardiovascular Diseases (J.B.G.), Mayo Clinic, Rochester, MN.

Sara Saberi

Andrew Wang

Mark Sherrid

NYU Langone Health, New York, New York, United States

Paul C. Cremer

Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (M.Y.D., K.W., P.C.C., S.E.N.), Cleveland Clinic, OH.

Neal K. Lakdawala

Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston

Albree Tower-rader

MASSACHUSETTS GEN HOSP, Boston, Massachusetts, United States

David Fermin

Corewell Health, Grand Rapids, Michigan, United States

Srihari S. Naidu

Department of Cardiology, Westchester Medical Center, Valhalla, NY (S.S.N., A.J.S.).

Nicholas G. Smedira

Hypertrophic Cardiomyopathy Center (M.Y.D., N.G.S.), Cleveland Clinic, OH.

Hartzell Schaff

MAYO CLINIC, Rochester, Minnesota, United States

Zhiqun Gong

Bristol Myers Squibb, Princeton, NJ

Lana Mudarris

Bristol Myers Squibb, Princeton, NJ (Z.G., L.M., K.L., A.J.S.).

Kathy Lampl

Bristol Myers Squibb, Princeton, NJ (Z.G., L.M., K.L., A.J.S.).

Amy J. Sehnert

Department of Cardiology, Westchester Medical Center, Valhalla, NY (S.S.N., A.J.S.).

Steven E. Nissen

Cleveland Clinic Coordinating Center for Clinical Research (C5 Research), Cleveland Clinic, Cleveland